Assessing the Latest Evidence for Optimal DOAC Reversal
More than 6 million individuals in the United States are currently taking anticoagulants for thrombosis and thromboembolic complications related to other conditions and events. While direct acting anticoagulants (DOACs) have a favorable bleeding profile compared with traditional therapies, bleeding remains a serious adverse event of treatment. Multidisciplinary management of DOAC-related bleeding demands that clinicians who treat individuals taking these drugs fully understand available, individualized strategies for anticoagulant reversal and bleeding management.
In this CME/CE activity, a multidisciplinary expert faculty panel examines the latest evidence on the optimal management of DOAC-associated bleeding from the published literature as well as presentations at recent major medical meetings. Through the program, learners will be provided with the clinical context of each article or presentation, the strengths and limitations of recent studies, and the faculty’s perspective on whether and how new evidence should translate into changes in routine clinical care.
Clinicians (MDs, NPs, PAs, RNs) in the hematology, cardiology, gastroenterology, emergency medicine, neurology, and surgical specialties; primary care providers (MDs, NPs, PAs, RNs); and pharmacists on the hospital formulary
At the conclusion of this activity, participants should be better able to:
- Evaluate risk of adverse events (AEs) associated with the use of direct oral anticoagulants (DOACs) and identify patients who are at elevated risk for bleeding
- Differentiate between mechanisms of action of DOAC agents to ensure selection of the appropriate reversal strategy when needed
- Interpret the efficacy, safety, and pharmacodynamics data from recent and relevant clinical trials of DOAC reversal agents
- Apply consensus guidelines in the proper selection of strategy and drug dosing and, if applicable, the management of DOAC-associated bleeding
Krishna Gundabolu, MBBS
Assistant Professor, Internal Medicine
Division of Hematology & Oncology
University of Nebraska Medical Center
Dr. Gundabolu does not have any relevant financial relationships to disclose.
Peter J. Kudenchuk, MD, FACP, FACC, FAHA, FHRS
Professor of Medicine
Department of Medicine - Division of Cardiology, Arrhythmia Services
University of Washington Medical Center
Dr. Kudenchuk does not have any relevant financial relationships to disclose.
Accredited by Haymarket Medical Education
In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Interprofessional Continuing Education (IPCE) Credit
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
AMA PRA Category 1 CreditTM
Haymarket Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Contact Hour
This activity is awarded 1.0 contact hour (based on 60 minutes per contact hour).
ACPE Continuing Pharmacy Education Credit
This knowledge-based activity JA4008232-0000-21-005-H01-P qualifies for 1.0 contact hour of continuing pharmacy education credit.
- 1.00 AMA PRA Category 1 Credit™
This course is offered through myCME.
To take this course you will be redirected to myCME's website. You must login or create an account with myCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!